Potential of Using qFibrosis Analysis to Predict Recurrent and Survival Outcome of Patients with Hepatocellular Carcinoma after Hepatic Resection
Hsiao, Chih-Yang, et al. Oncology 1-11 (2024)
Categories: Publications
Leukotriene B4 receptor 1 (BLT1) does not mediate disease progression in a mouse model of liver fibrosis
Coyne, Erin., et al. Biochem J; 481 (3): 177–190.
JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis
Xie, Li, et al. Clinical and Molecular Hepatology 30.2 (2024): 206.
Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions
Ratziu, Vlad, et al. Journal of Hepatology. October 23, 2023 DOI:https://doi.org/10.1016/j.jhep.2023.10.015
Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection
Zhang, Mengyang and Chen, Shuyan, et al. Journal of Medical Virology 95.10 (2023): e29156.
Digital pathology for nonalcoholic steatohepatitis assessment
Arun J. Sanyal, Prakash Jha & David E. Kleiner. Nat Rev Gastroenterol Hepatol 21, 57–69 (2024).
Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models
Wang, Xiao-Xiao, et al. Frontiers in Medicine 10 (2023): 1172058.
Caloric Restriction Combined with Immobilization as Translational Model for Sarcopenia Expressing Key- Pathways of Human Pathology
de Jong, Jelle CBC, et al. Aging and Disease 14.3 (2023): 937.
Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study
Anstee, Quentin M., et al. Hepatology: 10-1097.
Second-Harmonic Generated Quantifiable Fibrosis Parameters Provide Signatures for Disease Progression and Regression in Nonalcoholic Fatty Liver Disease
Ng, Nicole, et al. Clinical Pathology 16 (2023): 2632010X231162317.